Compare Stocks

→ “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$1.19	$1.79	$1.08 ▼ $5.50	$9.43M	0.96	12,181 shs	3,902 shs
ASPCF Acerus Pharmaceuticals	$0.22	$0.22	$0.22 ▼ $8.16	$1.70M	0.69	1,500 shs	N/A
LTUS Lotus Pharmaceuticals	$0.01	$0.01	$0.00 ▼ $0.01	$13.47M	-0.42	2,097 shs	39,766 shs
QBIO Q BioMed	$0.00	$0.00	$0.00 ▼ $0.02	$29K	1.72	538 shs	N/A

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	0.00%	-1.65%	-36.02%	-55.01%	-68.68%
ASPCF Acerus Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
LTUS Lotus Pharmaceuticals	0.00%	-28.57%	0.00%	+17.65%	-54.55%
QBIO Q BioMed	0.00%	0.00%	-33.33%	-75.00%	-98.55%

“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)

Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.

Find out why right here (and see what you can do to get in too with just a few dollars).

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ASPCF Acerus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LTUS Lotus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
QBIO Q BioMed	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A
ASPCF Acerus Pharmaceuticals	N/A	N/A	N/A	N/A
LTUS Lotus Pharmaceuticals	N/A	N/A	N/A	N/A
QBIO Q BioMed	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	($0.03) per share	N/A
ASPCF Acerus Pharmaceuticals	$2.12M	0.80	N/A	N/A	($3.38) per share	-0.07
LTUS Lotus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
QBIO Q BioMed	$280K	0.10	N/A	N/A	($0.11) per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$10.01M	N/A	0.00	∞	N/A	N/A	N/A	N/A	5/6/2024 (Estimated)
ASPCF Acerus Pharmaceuticals	-$33.82M	-$3.57	N/A	∞	N/A	-924.33%	N/A	-74.62%	N/A
LTUS Lotus Pharmaceuticals	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
QBIO Q BioMed	-$2.05M	-$0.03	N/A	∞	N/A	N/A	N/A	N/A	5/26/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
ASPCF Acerus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LTUS Lotus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
QBIO Q BioMed	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.95	0.95
ASPCF Acerus Pharmaceuticals	N/A	0.67	0.34
LTUS Lotus Pharmaceuticals	N/A	N/A	N/A
QBIO Q BioMed	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
ASPCF Acerus Pharmaceuticals	N/A
LTUS Lotus Pharmaceuticals	N/A
QBIO Q BioMed	N/A

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	61.80%
ASPCF Acerus Pharmaceuticals	N/A
LTUS Lotus Pharmaceuticals	N/A
QBIO Q BioMed	28.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	9	7.92 million	3.03 million	Not Optionable
ASPCF Acerus Pharmaceuticals	14	7.71 million	N/A	Not Optionable
LTUS Lotus Pharmaceuticals	233	2.69 billion	N/A	Not Optionable
QBIO Q BioMed	3	145.10 million	104.18 million	Not Optionable

ASPCF, LTUS, QBIO, and AKTX Headlines

Source	Headline
	E&Q Master Cordless Gutta Percha Obturator from Meta BioMed news-medical.net - March 24 at 4:19 AM
	Clearside Biomedical Q4 2023 Earnings Preview msn.com - March 11 at 7:34 PM
	Q BioMed Stock (OTC:QBIO) Dividends: History, Yield and Dates benzinga.com - February 24 at 3:23 AM
	Biogen Inc. (BIIB) Lags Q4 Earnings and Revenue Estimates msn.com - February 13 at 1:26 PM
	Bioxyne’s Q2 FY24 revenue surpasses $2.5m on Aussie medicinal cannabis growth msn.com - January 28 at 11:09 PM
	Q BioMed Inc QBIO morningstar.com - November 16 at 1:23 PM
	Biomedical Sciences PhD Program uwyo.edu - November 13 at 2:32 PM
	Q&A: How generative AI could help accelerate biomedical research phys.org - November 6 at 8:46 AM
	QBIO Q BioMed Inc. seekingalpha.com - August 18 at 4:51 AM
	Q BioMed’s chemotherapeutic Uttroside B gets US patent and notice of allowance in Europe pharmabiz.com - April 17 at 9:36 AM
	Q BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder value proactiveinvestors.com - April 14 at 10:53 AM
	Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe finance.yahoo.com - April 14 at 10:53 AM
	Q BioMed Stock (OTC:QBIO), Quotes and News Summary benzinga.com - March 3 at 4:23 PM
	Q BioMed gets notice of allowable US patent for liver cancer treatment Uttroside B proactiveinvestors.com - February 10 at 3:27 PM
	Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office finance.yahoo.com - February 10 at 8:27 AM
	Short Volatility Alert: Q Biomed Inc benzinga.com - January 12 at 2:36 PM
	Q BioMed Inc. (QBIO) finance.yahoo.com - January 1 at 5:15 PM
	Q BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin Research proactiveinvestors.com - November 14 at 2:22 PM
	Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC. finance.yahoo.com - November 14 at 9:20 AM
	Q BIOMED PROVIDES SHAREHOLDER UPDATE prnewswire.com - October 11 at 8:38 AM
	Q Biomed announces patent for groundbreaking GDF15 biomarker for glaucoma detection and treatment proactiveinvestors.com - September 27 at 1:02 PM
	Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER finance.yahoo.com - September 27 at 1:02 PM
	Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc. finance.yahoo.com - August 25 at 10:16 AM
	What to Expect at BIOMEDevice Boston mddionline.com - August 10 at 3:59 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Akari Therapeutics

NASDAQ:AKTX

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Acerus Pharmaceuticals

OTCMKTS:ASPCF

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.

Lotus Pharmaceuticals

OTCMKTS:LTUS

Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.

Q BioMed

OTCMKTS:QBIO

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial